Evidence map›Paper›PMID 33650100›Full record

Trial reportBritish journal of haematology2021

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.

Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, William Wilson, Richard Jenner, Gavin Pang, Sumaiya Kamora, Matthew Streetly, Rakesh Popat, Ceri Bygrave and 14 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Cancer reports (Hoboken, N.J.) · 2024
    Review
  7. Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 1 country.

Marquita CamilleriHaematology Department, University College Hospitals, London, UK.ORCID 0000-0002-4161-8275
Maria CuadradoHaematology Department, University College Hospitals, London, UK.
Elizabeth PhillipsDivision of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester, UK.
William WilsonCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Richard JennerCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Gavin PangCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Sumaiya KamoraCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Matthew StreetlyHaematology Department, Guys and St Thomas' NHS Trust, London, UK.
Rakesh PopatHaematology Department, University College Hospitals, London, UK.ORCID 0000-0001-6553-4618
Ceri BygraveUniversity Hospital of Wales, Cardiff, UK.ORCID 0000-0002-1571-0692
Roger OwenHMDS Laboratory, St James' Institute of Oncology, Leeds, UK.
James CavenaghHaematology Department, Barts Health NHS Trust, London, UK.
Mike ChapmanHaematology Department, Cambridge Institute for Medical Research, Cambridge, UK.
Jonathan SiveHaematology Department, University College Hospitals, London, UK.ORCID 0000-0002-1393-2793
Lydia EccersleyHaematology Department, Barts Health NHS Trust, London, UK.
Michael SheaffCellular Pathology Department, Barts Health NHS Trust, London, UK.
Reuben BenjaminHaematology Department, Kings College Hospital, London, UK.
Karthik RamasamyHaematology Department, Oxford University Hospitals NHS Trust, Oxford, UK.
Gordon CookLeeds Institute of Clinical Trial Research, University of Leeds, Leeds, UK.ORCID 0000-0003-1717-0412
Andres VirchisHaematology Department, Royal Free Hospitals NHS Trust, London, UK.
Selina J ChavdaHaematology Department, University College Hospitals, London, UK.ORCID 0000-0002-1359-9847
Laura Clifton-HadleyDivision of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester, UK.
Marie Anne ScullyHaematology Department, University College Hospitals, London, UK.ORCID 0000-0002-2443-6517
Kwee YongHaematology Department, University College Hospitals, London, UK.ORCID 0000-0002-6487-276X
University College Hospital · GBCancer Research UK · GBBarts Health NHS Trust · GBUniversity of Manchester · GBGuy's Hospital · GBKing's College Hospital · GBOxford University Hospitals NHS Trust · GBSt James's University Hospital · GBThe Royal Free Hospital · GBUniversity Hospital of Wales · GBUniversity of Leeds · GB

Funding

Cancer Research UK 24724Cancer Research UK C9203/A17750Medical Research Council MC_UU_00025/10
6 · The paper itself

Abstract

Proteasome inhibitors have been associated with thrombotic microangiopathy (TMA) - a group of disorders characterised by occlusive microvascular thrombosis causing microangiopathic haemolytic anaemia, thrombocytopenia and end-organ damage. To date, carfilzomib-associated TMA has predominantly been described in relapsed/refractory myeloma patients. We report eight patients with newly diagnosed myeloma who experienced TMA events while receiving carfilzomib on the phase II CARDAMON trial. The first three occurred during maintenance single-agent carfilzomib, two occurred at induction with carfilzomib given with cyclophosphamide and dexamethasone (KCd) and three occurred during KCd consolidation. At TMA presentation 6/8 were hypertensive; 7/8 had acute kidney injury and in three, renal impairment persisted after resolution of TMA in other respects. The mechanism of carfilzomib-associated TMA remains unclear, though patients with known hypertension seem particularly susceptible. Given the first three cases occurred during maintenance after a longer than five-week treatment break, a protocol amendment was instituted with: aggressive hypertension management, carfilzomib step-up dosing (20 mg/m

Indexed as

Acute Kidney InjuryMultiple MyelomaThrombotic MicroangiopathiesAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDexamethasoneFemaleHumansMaleMiddle AgedOligopeptidescarfilzomibCyclophosphamideDexamethasoneOligopeptidescarfilzomibclinical trialsmyelomathrombocytopeniathrombotic haemolytic anaemias

Identifiers

PMID33650100
PMCPMC11497300
OpenAlexW3133504941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.